Navigation Links
Cellectricon Receives Milestone Order for Cellaxess(R)HT, the World's First High Throughput RNAi Screening System
Date:11/12/2008

GOTHENBURG, Sweden, November 12 /PRNewswire/ -- Cellectricon, a leading provider of advanced screening solutions for drug discovery, has today received its most significant and largest single order to date. The order includes three Cellaxess(R)HT systems and the customer is a leading US biotech firm.

"An order of this magnitude proves the system's unique features and value, and validates Cellectricon's strategy to bring state-of-the-art products for drug discovery and research to the market through world-class customer collaborations." says Jonas Ohlsson, CEO at Cellectricon. "Cellectricon has developed the Cellaxess(R)HT system in close collaboration with leading pharmaceutical companies and academic research groups to meet the rapidly growing demand for a true high throughput transfection screening technology, capable of reagent-free delivery of genetic material to biologically relevant cell types."

Cellaxess(R)HT is the world's first fully automated workstation for high throughput RNAi screening on biologically relevant cell types. The system enables reagent free delivery of siRNA and cDNA to a wide range of primary cells and cell lines with excellent efficiency and viability at a throughput of 50, 000 wells per day. Cellaxess(R)HT is first of its kind on the market and will significantly impact target discovery by providing key functional data in relevant primary human cells.

About Cellectricon

Cellectricon AB, a Swedish biotech company, successfully provides groundbreaking products to the pharmaceutical and biotechnology market. The company utilizes state-of-the-art interfaces to biological systems by employing novel microfluidic technologies. Cellectricon's products address critical bottlenecks in the drug discovery process and have been adopted by top-reference customers, including nine of the top ten pharmaceutical companies. In 2007 the company increased its annual revenue by almost 50%. In 2008-2009 the company is launching two pioneering large-scale screening platforms developed in close collaboration with leaders in the pharmaceutical industry. Used in pre-clinical pharmaceutical development, the Cellaxess(R)HT System enables high throughput RNAi screening and the Dynaflow(R)HT System greatly advances ion channel drug discovery.

Contact Details:

Jonas Ohlsson, CEO

Phone: +46(0)709-73-47-92

E-mail: jonas.ohlsson@cellectricon.com

Susanne Fagerlund

VP Marketing & Communications

Phone: +46(0)31-760-35-15

E-mail: susanne.fagerlund@cellectricon.com


'/>"/>
SOURCE Cellectricon AB
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
2. Share Issue Gives Cellectricon SEK 89 Million to Continue its Rapid Market Expansion
3. China Medical Technologies Receives SFDA Approval for Breast Cancer HER-2 FISH Probe
4. West Michigans Newest Medical Device Company Receives Support from the West Michigan Science & Technology Initiative and EDF Ventures
5. ProtoKinetix Receives Independent Confirmation of AAGP Anti-Inflammatory Action
6. Valor Medical Closes $1.4 Million Convertible Debt and Receives ISO 13485 Certification
7. Aposense Receives Frost & Sullivan Technology Innovation of the Year Award
8. Solos Endoscopy, Inc. Receives Purchase Order from Connecticut Hospital
9. Caraco Pharmaceutical Laboratories, Ltd. Receives FDA Warning Letter
10. Environmental Tectonics Corporations Simulation Division Receives New ADMS Contract from Netherlands Institute for Safety
11. InNexus Biotechnology Receives Patent Grants in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... of a complex biological network, a depiction of a system of linkages and ... Dmitry Korkin, PhD, associate professor of computer science at Worcester Polytechnic Institute (WPI) ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Surgical Wound Market with the addition of its newest module, US Hemostats & ... market for thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)... , Oct. 11, 2017  VMS BioMarketing, a leading provider ... nationwide oncology Clinical Nurse Educator (CNE) network, which will launch ... for communication among health care professionals to enhance the patient ... office staff, and other health care professionals to help women ... cancer. ...
Breaking Biology Technology:
(Date:4/11/2017)... , Apr. 11, 2017 Research and ... Market 2017-2021" report to their offering. ... The global eye tracking market to grow at a ... report, Global Eye Tracking Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
(Date:3/30/2017)... HONG KONG , March 30, 2017 ... developed a system for three-dimensional (3D) fingerprint identification by adopting ground ... technology into a new realm of speed and accuracy for use ... applications at an affordable cost. ... ...
Breaking Biology News(10 mins):